Business
Appointment of Non-Executive Director
Appointment of Non-Executive Director.
About this update from Valirx Plc
[{"type":"text","content":"\n \nFor immediate release:\n\nValiRx appoints James Nicholas Thorniley as non-executive director\n\nValiRx plc (AIM: VAL) (\"ValiRx\" or the \"Company\"), the cancer therapeutics\ncompany, today announces that it has appointed James Nicholas (\"Nick\")\nThorniley (age 62) to the Board as a non-executive director with immediate\neffect.\n\nNick Thorniley's City career spans some 38 years. Latterly, he has concentrated\non corporate broking having been a director and head of corporate broking at\nboth Investec Securities (2002-2005) and, previously, at Panmure Gordon\n(1990-2002).\n\nNick Thorniley currently holds 11,812,500 ordinary shares of 0.2p each in the\nCompany (\"Ordinary Shares\") representing 1.33% of the issued Ordinary Share\ncapital of the Company. In addition, he holds an entitlement to a further\n3,150,000 Deferred Consideration Shares, details of which are included in the\nCompany's admission document dated 8 September 2006.\n\nAnthony Moore, Chairman of ValiRx, commented:\n\n\"Nick has had an extensive career in corporate broking and played an\ninstrumental role in the Company's reverse takeover and admission to AIM. Going\nforward, we believe he will be a valuable resource to the Board as we look to\ntarget further acquisition and investment opportunities.\"\n\nThere is no further information to disclose under Schedule Two paragraph (g) of\nthe AIM Rules.\n\n- ENDS -\n\nInformation on ValiRx plc\n\nValiRx is a biopharmaceutical development company that is building a portfolio\nof complementary cancer-related therapeutic and diagnostic technologies. It\ncurrently holds stakes in Cronos Therapeutics Limited and Morphogenesis Inc:\n\n * Cronos Therapeutics Limited holds licenses to two innovative and\n potentially market changing technologies, GeneICE and HyperGenomics. The\n Company has been informed by the European Patent Office that it is to\n receive the granting of a patent for its GeneICE cancer technology.\n \n * Morphogenesis Inc. is developing a portfolio of cell therapy products for\n the treatment of chronic disorders. Its most advanced product is ImmuneFxâ„¢\n for which it recently received a patent from the US patent office.\n \nValiRx is headquartered in London, England.\n\n\nContact Details:\n\n ValiRx plc WH Ireland Limited GTH Communications \n \n Dr Satu Vainikka David Youngman Toby Hall / Jade M...